AVI Biopharma About
Avi Biopharma: AVI is a biopharmaceutical company developing
drugs to treat life-threatening diseases using third-generation antisense technology.
They have completed eleven clinical trials with their NeuGene®
antisense drugs in more than 300 subjects addressing cardiovascular restenosis,
cancer, polycystic kidney disease and drug metabolism. Their most advanced
clinical program is in cardiovascular restenosis. They have completed Phase
II trials evaluating their antisense drug, Resten-NG
Their NeuGene drug candidates have shown antiviral activity in preclinical
and field trials against a broad group of RNA viruses, including hepatitis C virus,
West Nile virus, SARS coronavirus, Dengue fever virus and Ebola virus. AVI
has evaluated Avicine,
a therapeutic cancer vaccine, in six clinical trials involving colorectal
and pancreatic cancer.
Pipeline
Chart for Avi Biopharma NeuGene
Clinical Development Chart --NeuGene antisense compounds include
use in drug metabolism and in treating cardiovascular disease, cancer, polycystic
kidney disease, and viral diseases
Key
Statistics fo
Avi Biopharma
More on Avi Biopharma:
Basic Chart
for Avi Biopharma